Skip to main content
Premium Trial:

Request an Annual Quote

Foundation Medicine, Eisai Ink Personalized Med Alliance

NEW YORK (GenomeWeb News) – Foundation Medicine today said that it has signed a multi-year alliance with Eisai to conduct genomic profiling and diagnostic discovery for an oncology therapeutic candidate being developed by the Japanese drug firm.

The Cambridge, Mass.-based firm said that the goal of the collaboration is to prospectively identify specific genomic alterations in each patient's tumor. The results would be used for patient stratification, for guiding further drug development, and potentially for the commercialization of molecular diagnostic products.

Foundation Medicine will receive an upfront payment from Eisai and is eligible for future diagnostic rights. Further terms of the alliance were not disclosed.

"This collaboration represents the continued advancement of our partnership strategy as we gain greater understanding into the key alterations driving tumor growth," Foundation Medicine President and CEO Michael Pellini said in a statement. "By using our comprehensive genomic profile to inform trial enrollment and outcomes analysis, Eisai can reveal the genomic drivers of an individual patient's disease and may be able to more rapidly advance effective targeted treatments for cancer."

The deal with Eisai is the latest in a string for Foundation Medicine, which has inked collaborations with Array BioPharma, N-of-One, Novartis, Clovis, and Johnson & Johnson.

Last month the firm raised $42.5 million in a Series B round of financing.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.